PARIS: The first new asthma pill in nearly 20 years has led to a sharp improvement in symptoms for chronic sufferers of the disease, according to an early test of the drug.
WASHINGTON: U.S. regulators have declined to approve Novartis' so-called biosimilar copy of Amgen's Neulasta drug that fights infections in cancer patients, the Swiss drugmaker said on Tuesday.
CHICAGO: A Novartis trial of two drugs against an aggressive lung cancer bodes well for broadening their use beyond melanoma, the Swiss drugmaker told the American Society of Clinical Oncology's conference in Chicago on Tuesday. Novartis's Tafinlar and Mekinist combination shrank tumors in 63 percent of the trial's 57 people with BRAF V600E-mutation positive non-small cell lung cancer who had failed on chemotherapy, the company said, citing a Phase II study.
LONDON: Efforts by Novartis to defend its blockbuster cancer drug Afinitor against competitors got a boost on Thursday from European regulators, who approved it for use on certain types of advanced gastrointestinal and lung neuroendocrine tumors.
The Ankara Chief Prosecutor has launched an investigation into the Turkish unit of Swiss drugmaker Novartis, local media reported on Friday, after allegations it benefited from bribery.
The U.S. Food and Drug Administration approved Novartis AG's injectable drug, Cosentyx, to treat adults with a moderate to severe skin disease called plaque psoriasis.